NBIX - Neurocrine gets FDA breakthrough therapy status for crinecerfont
2023-12-05 17:16:18 ET
More on Neurocrine Biosciences
- Neurocrine Biosciences: Fear Not The IRA
- Neurocrine Biosciences, Inc. (NBIX) Q3 2023 Earnings Call Transcript
- Neurocrine Biosciences, Inc. 2023 Q3 - Results - Earnings Call Presentation
- Neurocrine settles all patent disputes related to movement disorder therapy
- Neurocrine reports Phase 2 study failures for two drug candidates
For further details see:
Neurocrine gets FDA breakthrough therapy status for crinecerfont